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Paraneoplastic Cushing’s syndrome  
in a patient with small cell lung cancer: 
case report
ABSTRACT
We discuss the case of small-cell lung cancer patient with clinical features of paraneoplastic Cushing’s 
syndrome. The primary symptoms included electrolyte imbalance, glucose intolerance, and increased 
oedemas of the lower extremities. In January 2016, the patient's performance status was 2 in ECOG scale 
and antineoplastic treatment with carboplatin and etoposide was initiated. Following the 2nd chemotherapy 
cycle symptoms of paraneoplastic syndrome significantly were alleviated and performance status improved 
(grade 1), allowing a change of chemotherapy protocol to a more standard one (cisplatin and etoposide). At 
the time of the subsequent chemotherapy cycles the patent's good general condition was maintained. Use of 
causative treatment allowed achievement of significant clinical improvement and recovery of laboratory values.
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Introduction
Paraneoplastic syndrome is a clinical condition re-
lated to malignancy but not directly resulting from local 
tumour burden or distant metastases. The symptoms of 
paraneoplastic syndrome could precede other clinical 
features of the cancer. There are two basic mechanisms 
of development of paraneoplastic syndromes: the first 
is associated with hormones and cytokines produced by 
neoplastic cells, and the second results from the activity 
of antibodies produced against cancer cells that have an 
impact on healthy tissues [1, 2].
The incidence of paraneoplastic syndromes is rela-
tively high, and they affect approximately 10% of cancer 
patients [1]. The prevalence depends on the type and 
stage of cancer. Although very rare, paraneoplastic 
Cushing’s syndrome results from ectopic production of 
adrenocorticotropic hormone (ACTH). It affects 1–5% 
of all patients with diagnosis of Cushing’s syndrome 
[3]. In approximately half of cases this syndrome is 
diagnosed in patients with small-cell lung cancer or 
neuroendocrine cancers of the respiratory tract [2–4]. 
The syndrome of ectopic ACTH release is also seen in 
patients with thymic neoplasms, pheochromocytoma, 
and medullary thyroid cancer [1, 3].
In the presented paper we discuss a history of female 
patient with paraneoplastic Cushing’s syndrome in the 
course of small-cell lung cancer.
Case report
A 58-year-old female patient with stage IV small-cell 
lung cancer was admitted in January 2016 to the Clinic 
of Chemotherapy of the Oncology Department at the 
Medical University of Łódź. Her performance status 
was assessed as 2 in the ECOG (Eastern Cooperative 
Oncology Group) Scale, with dyspnoea at rest and severe 
oedemas of the lower extremities. The patient had a long 
medical history of many concomitant diseases (type 2 
diabetes, hypertension grade 2, and hyperthyreosis 
after treatment with radioactive iodine in 2013), mitral 
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insufficiency, and tricuspid regurgitation. She was an 
ex-smoker with 35 pack-years in her history.
The current disease was diagnosed in October 
2015. At this time the patient was not qualified for 
elective operation of total vaginal and uterine prolapse 
due to hyperthyreosis. Further diagnostic tests were 
planned; however, the patient was discharged at her 
request, against medical advice.
In November 2015 the patient was hospitalised in 
internal medicine department of regional hospital due 
to reduced exercise tolerance, heart palpitations, pro-
gressive oedema of the lower extremities, and increased 
of abdominal circumference. Significant hyperglycaemia 
was revealed in laboratory tests. Type 2 diabetes was di-
agnosed and insulin treatment introduced. Chest X-ray 
and abdominal ultrasound (USG) were performed, and 
then the diagnostics were upgraded by chest computed 
tomography (CT), which revealed a tumour of the 
right lung, a pancreatic tumour, and a tumour of left 
suprarenal gland (probably metastatic). The patient 
was discharged with the recommendation to urgently 
contact an oncology specialist.
Fine-needle aspiration of the pancreatic mass was 
performed in December 2015. Additional bronchoscopy 
was planned, but the patient withdrew consent. Due to 
ambiguous results of cytology (neuroendocrine cancer 
cells present) oligobiopsy of the tumour was performed. 
Oligobiopsy of pancreas can not be considered as a rou-
tine test, however, low-differentiated small-cell cancer 
of most probable lung origin was diagnosed (Ki67 index 
— 100%).
In January 2016 the patient was re-hospitalised in 
the Emergency Department of Nicolaus Copernicus 
Regional Specialist Hospital in Łódź due to significant 
worsening of general health, progressive dyspnoea at 
rest with chest tightness and lower extremities oedema, 
as well as low urine output. Laboratory tests revealed 
marked hypokalaemia (3.0 mmol/L). The patient was 
referred to the Palliative Care Unit, where supportive 
treatment was administered with improvement of gen-
eral condition. The patient was referred to the Clinic of 
Chemotherapy of the Oncology Department for urgent 
introduction of causative treatment.
At the time of admission to the clinic physical 
evaluation revealed features of superior vena cava 
syndrome (widened neck outline, enlarged veins on the 
left side of the chest), exophthalmos, soft package of 
lymph nodes in the left supraclavicular area, and pasty 
oedema of lower extremities up to the level of knee 
joints). Respiratory murmurs over the right lung were 
significantly weakened. The abdomen was raised above 
chest level, and during palpation it was soft, painless, and 
without pathological mass. Due to Cushingoid posture 
(visceral obesity), round face shape, and numerous 
claret-coloured stretch marks on the skin, a diagnosis of 
Cushing’s syndrome was considered for the first time.
Laboratory tests revealed hypokalaemia (2.8 mmol/L) 
and lymphopaenia (1.09 × 103/µL). Serum ACTH and 
neurospecific enolase (NSE) concentration was addi-
tionally evaluated, and the values were significantly 
increased [173.0 pg/mL (normal range 7.9–66.1 pg/mL) 
and 720 µg/mL (normal range 16.3 µg/mL), respectively].
Due to clinical symptoms and increased ACTH 
serum concentration, paraneoplastic Cushing’s syn-
drome was diagnosed. Taking into consideration the 
significant dynamics of cancer and the demand for quick 
introduction of causative treatment, no additional tests 
to confirm ectopic release of ACTH were performed 
(provocative test after administration of 8 mg of dexa-
methasone, octreotide test).
Due to hyperthyreosis CT scans with contrast in 
order to assess the current clinical stage of disease 
were temporarily deferred. However, chest X-ray and 
abdominal USG revealed abnormalities — abnormal 
mass localised in front of right lung hilus (40 mm and 
26 mm in diameter, respectively), widening of right supe-
rior mediastinum with modelling of trachea to left side, 
vestigial effusion in interlobular fissures, enlargement 
of the cardiac silhouette, tuberous, hypoechoic, solid 
change with the size 98 × 54 × 60 mm in the area of 
the tail of the pancreas and tumour of left suprarenal 
gland with the size of 86 × 50 mm.
Supportive management was immediately intro-
duced (including potassium supplementation, diuretics, 
eplerenone, chlorthalidone, propranolol), and insulin 
therapy was continued. After achieving normokalaemia 
therapy with digoxin was added. 
Due to the presence of a mediastinal mass affecting 
systemic haemodynamics as well as the need for restrict-
ed fluid supply, systemic treatment with carboplatin and 
etoposide was started, with the intention of changing to 
cisplatin after improvement of the patent's general state.
At chemotherapy cycle 2. the patient’s performance 
status was remarkably better (ECOG 1), with no dys-
pnoea at rest and small oedema of the lower extrem-
ities. The treatment was changed to typical protocol 
(cisplatin and etoposide).
At chemotherapy cycle 4. the patient’s performance 
status was still good (ECOG 1), without dyspnoea or oe-
dema of the lower extremities. Serum potassium concen-
tration was within normal range, and ACTH and NSE 
concentrations normalised (64.9 pg/mL and 12.3 µg/mL, 
respectively). Repeated chest X-ray revealed complete 
response of tumour mass previously located in front of 
the right hilus and partial remission of the mediastinal 
mass, with no increased heart silhouette. Abdominal 
USG revealed partial remission of the tumour mass in 
the pancreatic tail and left suprarenal gland.
Systemic treatment was terminated after six chemo-
therapy cycles. Good performance status was maintained, 
similarly to normalisation of laboratory values and partial 
remission in imaging evaluations. The patient did not 
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agreed to have elective brain irradiation and failed to 
attend an appointed follow-up visit in the oncology outpa-
tient clinic.The subsequent fate of the patient is unknown.
Discussion
Paraneoplastic Cushing’s syndrome affects 1–5% 
of patients with SCLC [2–4]. In a retrospective trial, 
Nagy-Mignotte et al. indicated that intercurrent ectopic 
release of ACTH in patients with SCLC is associated 
with more advanced clinical stage, poor response to 
systemic treatment, and shortened overall survival 
[4]. The reasons for poorer prognosis include reduced 
chemosensitivity, higher clinical stage, as well as higher 
infection risk (among others, opportunistic infections 
and sepsis resulting from hypercortisolaemia) [1, 3, 4]. 
Accordingly, normalisation of cortisol concentration 
before systemic treatment is advised. In order to reduce 
hypercortisolaemia, steroidogenesis inhibitors and 
corticosteroids agonists (e.g. ketoconazole, mitotane, 
aminoglutetymide, and metapyrone) are used [1–4].
Paraneoplastic Cushing’s syndrome could be distin-
guished from classic Cushing’s syndrome and increased 
pituitary release of ACTH (Cushing’s disease) based 
on serum cortisol and ACTH concentration and brain 
CT (exclusion of pituitary tumours). The laboratory 
tests performed in order to assess this condition in-
clude a provocative test after 8 mg of dexamethasone 
(oral dexamethasone 2 mg every six hours for two days 
— measurement of cortisol concentration in daily urine 
collection at baseline and on the 2. day of dexametha-
sone administration) as well as octreotide test [1, 3, 4]. 
Corticotropin releasing factor (CRF)-stimulation test 
could also be performed; however, its specificity is not 
100% due to the sensitivity of some ectopic tumours 
producing ACTH to CRF. In cases of ectopic ACTH 
production cortisol is not suppressed due to continuous 
release of adrenocorticotropic hormone.
Cushing’s syndrome due to the increased ACTH 
production could result in increased blood pressure, 
hyperpigmentation of the skin, mental disorders, 
oedemas, glucose intolerance, abnormal fat tissue dis-
tribution, stretch marks on the skin, muscle weakness, 
and hypokalaemia alkalosis [1]. The main symptoms of 
paraneoplastic Cushing’s syndrome include electrolytic 
disturbances rather than morphological features of that 
syndrome because hypercortisolaemia is an acute state, 
and the patient survival time is too short to develop 
morphological changes [3]. This is very important 
in patients with suspected Cushing’s syndrome, to 
determine the source of ACTH release based on the 
aforementioned tests. Similarly to other endocrinology 
paraneoplastic syndromes, a characteristic feature of 
ectopic ACTH release is improvement of hormonal 
state and alleviation of symptoms during antineoplas-
tic treatment [2]. Management is based on control of 
hypercortisolaemia and metabolic complications as 
well as proper antineoplastic therapy.
Summary
The presented patient was diagnosed with para-
neoplastic Cushing’s syndrome based on characteristic 
clinical signs and symptoms (morphological features, 
increased ACTH serum activity, hyperglycaemia, 
hypokalaemia, lymphopaenia) and the presence of 
a typical picture of underlying malignancy. No ad-
ditional endocrine-related tests were performed to 
confirm ectopic release of ACTH. Proper supportive 
care together with active antineoplastic treatment led 
to considerable improvement of the patient’s general-
condition, partial cancer response, and normalisation 
of endocrine functions.
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